Search research articles
Contact Us
Filters
Showing results (131-140 of 205) with videos related to
Page
of 21
Sort By:
Future Oncology (London, England)
|
November 23, 2023
A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab
Christopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, et al.
Urologic Oncology
|
June 17, 2014
Micropapillary bladder cancer: current treatment patterns and review of the literature
Daniel L Willis, Thomas W Flaig, Donna E Hansel, et al.
European Urology
|
December 13, 2023
Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer
Wolfgang Beckabir, Sara E Wobker, Jeffrey S Damrauer, et al.
The Journal of Pathology
|
May 7, 2011
Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma
Hikmat A Al-Ahmadie, Gopa Iyer, Manickam Janakiraman, et al.
JAMA Oncology
|
July 7, 2018
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial
Karen A Autio, Robert Dreicer, Justine Anderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2021
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)
Thomas W Flaig, Catherine M Tangen, Siamak Daneshmand, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 12, 2016
Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer
Kimberley S Mak, Angela B Smith, Alec Eidelman, et al.
The Journal of Urology
|
October 28, 2025
Impact of renal mass biopsy on decision-making experience for clinical T1 renal masses
Kathryn H Gessner, Allison M Deal, Amir Feinberg, et al.
Urologic Oncology
|
December 17, 2013
Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy
Gregory R Pond, Giuseppe Di Lorenzo, Andrea Necchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2023
Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
Seth P Lerner, David J McConkey, Catherine M Tangen, et al.
Page
of 21
Search research articles
Search
Showing results (131-140 of 205) with videos related to
Sort By:
Page
of 21
Future Oncology (London, England)
|
November 23, 2023
A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab
Christopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, et al.
Urologic Oncology
|
June 17, 2014
Micropapillary bladder cancer: current treatment patterns and review of the literature
Daniel L Willis, Thomas W Flaig, Donna E Hansel, et al.
European Urology
|
December 13, 2023
Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer
Wolfgang Beckabir, Sara E Wobker, Jeffrey S Damrauer, et al.
The Journal of Pathology
|
May 7, 2011
Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma
Hikmat A Al-Ahmadie, Gopa Iyer, Manickam Janakiraman, et al.
JAMA Oncology
|
July 7, 2018
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial
Karen A Autio, Robert Dreicer, Justine Anderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2021
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)
Thomas W Flaig, Catherine M Tangen, Siamak Daneshmand, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 12, 2016
Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer
Kimberley S Mak, Angela B Smith, Alec Eidelman, et al.
The Journal of Urology
|
October 28, 2025
Impact of renal mass biopsy on decision-making experience for clinical T1 renal masses
Kathryn H Gessner, Allison M Deal, Amir Feinberg, et al.
Urologic Oncology
|
December 17, 2013
Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy
Gregory R Pond, Giuseppe Di Lorenzo, Andrea Necchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2023
Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
Seth P Lerner, David J McConkey, Catherine M Tangen, et al.
Page
of 21